Phase III clinical trial of [F-18]MK-6240 slated for 2018
CT images were used to create model
Greater outreach and education needed for these patients
Stringent eligibility criteria may be more cost-effective
May have implications for newly diagnosed patients and survivors
May eliminate need for pathologist review
Allows breast MR exams at a tenth of the conventional cost
May also help in targeting treatment
Workshop sheds light on key issues hospitals must address
Not everyone is convinced of controversial findings
Screening can start at age 30 instead of 65
Devices must be used in FDA-approved studies
Investigative SynCardia device sustains 11-year-old as he awaits transplant
Expands on 15-year partnership with WMCHealth
Researchers encourage clinicians to provide feedback
Linking brain region activity to medication efficacy
Could allow for faster diagnostic tests, smartphone app
More research needed to find a treatment
The benefits of interoperability come at a cost
Optional upgrade for ASPIRE Cristalle FFDM system
Cuts spinal registration down to 20 seconds
Pilot study data shows 34.5 percent drop in hospitalization rates
May provide long-term therapy for heart failure patients
Dr. Richard Pazdur appointed as director
Eliminates the complexity and high cost of separate contracts
Negotiating lowest prices for medical supplies and equipment
Aiming to bring quantitative MR to the clinical setting
MD Buyline predicts the next game-changing innovations
May detect cancer with cell phone images
Intermountain Heart Institute first to use during catheter ablation
Robotic system is designed to help surgeons with spine fusions
MGH and Mount Sinai team up
Designed for spine, cranial and trauma procedures
57 percent reduction in infection rate
More research needed for FDA approval
Cybersecurity concerns and physician disinterest needs to be addressed
Drastic reductions in prostate, breast, lung and colorectal cancer mortality
NIH awards $5 million grant
Quality of care wasn't compromised
Has the potential to prevent vision loss
Creating a smaller, more affordable proton solution
Shares have fallen 40 percent since Tuesday
Breast cancer targeting probes are showing promise in clinical trials
Noninvasive technology examines tau proteins
Appoints new CEO of McKesson Canada
Patients are either too well or too sick to benefit
Almost $1 billion in penalties since 2012
Neurosurgical is the largest segment
The 10-year deal is worth EUR 74 million
Builds on long-standing relationship
